[go: up one dir, main page]

AR078216A1 - Metodos para la inhibicion de la neurodegeneracion - Google Patents

Metodos para la inhibicion de la neurodegeneracion

Info

Publication number
AR078216A1
AR078216A1 ARP100100459A ARP100100459A AR078216A1 AR 078216 A1 AR078216 A1 AR 078216A1 AR P100100459 A ARP100100459 A AR P100100459A AR P100100459 A ARP100100459 A AR P100100459A AR 078216 A1 AR078216 A1 AR 078216A1
Authority
AR
Argentina
Prior art keywords
app
polypeptide
neurodegeneration
inhibited
exposure
Prior art date
Application number
ARP100100459A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR078216A1 publication Critical patent/AR078216A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se presentan métodos para la deteccion de compuestos que inhiben la neurodegeneracion. El desprendimiento de APP puede ser un marcador util para la neurodegeneracion, y los compuestos que inhiben el desprendimiento de APP son utiles como inhibidores de la neurodegeneracion. Dichos compuestos pueden ser utiles en el tratamiento y la prevencion de diversos trastornos y enfermedades neurologicos, y del dano neuronal, y pueden aumentar el crecimiento, la regeneracion o la supervivencia de tejido o células neuronales de mamíferos. Reivindicacion 1: Un método para la inhibicion de la neurodegeneracion, que comprende: (a) la exposicion de polipéptido DR6 y/o polipéptido APP a uno o más antagonistas de DR6 en condiciones donde la union de DR6 a APP es inhibida; (b) la exposicion de polipéptido p75 y/o polipéptido APP a uno o más antagonistas de p75 en condiciones donde la union de APP a p75 es inhibida; o (c) la exposicion de polipéptido DR6 polipéptido p75. y/o polipéptido APP a uno o más antagonistas de DR6 y p75, en condiciones donde la union de DR6 y p75 a APP es inhibida.
ARP100100459A 2009-02-18 2010-02-17 Metodos para la inhibicion de la neurodegeneracion AR078216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15354009P 2009-02-18 2009-02-18

Publications (1)

Publication Number Publication Date
AR078216A1 true AR078216A1 (es) 2011-10-26

Family

ID=42634431

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100459A AR078216A1 (es) 2009-02-18 2010-02-17 Metodos para la inhibicion de la neurodegeneracion

Country Status (13)

Country Link
US (1) US20120076785A1 (es)
EP (1) EP2399135A4 (es)
JP (1) JP2012518042A (es)
KR (1) KR20120011841A (es)
CN (1) CN102326083A (es)
AR (1) AR078216A1 (es)
AU (1) AU2010216107A1 (es)
BR (1) BRPI1005403A2 (es)
CA (1) CA2752171A1 (es)
IL (1) IL214647A0 (es)
MX (1) MX2011007567A (es)
TW (1) TW201034684A (es)
WO (1) WO2010096470A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
WO2014061749A1 (ja) * 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
US10295547B2 (en) * 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
EP3685662B9 (en) * 2015-03-16 2023-10-04 Regeneron Pharmaceuticals, Inc. Cell of a rodent exhibiting diminished upper and lower motor neuron function and sensory perception
EP3273982B1 (en) * 2015-03-26 2020-11-18 Suzhou Auzone Biological Technology Co., Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
EP3612190A4 (en) 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
JP2020535448A (ja) 2017-09-25 2020-12-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｒａｎタンパク質の検出のための免役アッセイ
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用
CN116829956A (zh) * 2023-02-28 2023-09-29 湖南乾康科技有限公司 用于检测蛋白生物标志物组的抗体在制备诊断ad、mci和其它类型老年痴呆的试剂盒中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
JP2000507828A (ja) * 1996-03-29 2000-06-27 ザ トラスティーズ オブ ボストン ユニバーシティー アルツハイマー病の診断および治療法
FI991197A0 (fi) * 1999-05-27 1999-05-27 Mart Saarma Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
AU2002255881A1 (en) * 2001-03-23 2002-10-08 University Of Utah Research Foundation Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
AU2002359459A1 (en) * 2001-12-17 2003-06-30 Eli Lilly And Company Treating b-cell mediated diseases by modulating dr6 activity
US20040191291A1 (en) * 2003-03-28 2004-09-30 Masaya Tohyama Composition and method for nerve regeneration
CN1849132A (zh) * 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
EP1682170A2 (en) * 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
JP4704435B2 (ja) * 2004-10-22 2011-06-15 ニューレジェニクス リミテッド ニューロン再生
CA2595800C (en) * 2005-01-24 2014-07-08 Cambridge Antibody Technology Limited. Specific binding members for ngf
CN101273060A (zh) * 2005-06-24 2008-09-24 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） 通过靶向肿瘤坏死因子受体的前配体装配域(plad)来缓解炎性关节炎
JP2010514700A (ja) * 2006-12-22 2010-05-06 ジェネンテック， インコーポレイテッド Ｄｒ６アンタゴニスト及び神経障害の治療におけるその使用法
US8501178B2 (en) * 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system

Also Published As

Publication number Publication date
WO2010096470A4 (en) 2011-04-14
CN102326083A (zh) 2012-01-18
JP2012518042A (ja) 2012-08-09
IL214647A0 (en) 2011-09-27
KR20120011841A (ko) 2012-02-08
TW201034684A (en) 2010-10-01
CA2752171A1 (en) 2010-08-26
MX2011007567A (es) 2011-09-28
US20120076785A1 (en) 2012-03-29
EP2399135A2 (en) 2011-12-28
AU2010216107A1 (en) 2011-08-18
WO2010096470A2 (en) 2010-08-26
EP2399135A4 (en) 2012-10-17
BRPI1005403A2 (pt) 2016-10-04
WO2010096470A3 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
AR078216A1 (es) Metodos para la inhibicion de la neurodegeneracion
ECSP21027049A (es) Inhibidores de la proteína tirosina fosfatasa
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
PE20070335A1 (es) Benzimidazoles sustituidos y metodos para su preparacion
IN2015DN00438A (es)
MX2011011735A (es) Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
EA201790357A1 (ru) Способ получения клеток-предшественников зрелой печени
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
AR064501A1 (es) Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
DOP2017000053A (es) Derivados de benzodiazepina citotóxicos
CR10427A (es) Quinazolinas para la inhibicion de pdk1
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
EA200970931A1 (ru) Аналоги гетероариламидов
SG11201809744YA (en) Method for improving salt tolerance of plant
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
WO2010117423A3 (en) Modulation of beta 2 adrenergic receptors by inhibitors of egln3 or pvhl
PE20170294A1 (es) Inhibidores de aldosterona sintasa
BR112018073227A2 (pt) compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
CO6382175A2 (es) Metodo para inhibir la cinasa del c-kit

Legal Events

Date Code Title Description
FB Suspension of granting procedure